Patients have little say in how brain implant trials are done. Ian Burkhart wants to change that

by | Nov 20, 2026 | Health

Patients have little say in how brain implant trials are done. Ian Burkhart wants to change that

The BCI Pioneers Coalition released a report last week containing 13 recommendations aimed at improving how clinical trials of implanted brain-computer interfaces are conducted. The recommendations target startups, researchers, and regulatory bodies, focusing on three primary areas: managing care after trials end, ensuring informed consent procedures, and protecting the privacy of neural data collected from participants.

Participants in BCI trials often face limited agency in research decisions despite the significant personal impact these studies have on their lives. Many individuals with conditions such as ALS enter these trials as a final option to restore communication, mobility, or autonomy. Ian Burkhart, who co-founded the coalition with other early-stage BCI users, emphasized that studies can extend for years and become deeply woven into participants’ daily experiences, underscoring the importance of meaningful participant input in trial design and management.

The emerging field is experiencing substantial growth, transitioning from early proof-of-concept research into a bustling ecosystem of neurotechnology startups attracting investor interest and running multiple safety and efficacy trials. This expansion has raised concerns among ethicists and researchers about protecting participant rights. Anna Wexler, an ethicist at UCLA, noted that current policies lack adequate safeguards, with potential solutions including mandatory insurance coverage and institutional commitments still under discussion.

Participants have reported uncertainty about study endpoints and what happens to devices and data after trials conclude. Informed consent documents are often structured to protect research institutions rather than participant interests, leaving participants with little practical choice but to accept terms or forgo treatment entirely. Long-term care for device users remains a significant concern, with questions about battery replacement, device maintenance, and company sustainability affecting participants’ ability to continue using implants after trials end.

Article Attribution | Read More at Article Source

Article summary produced by Claude AI